Free Trial
NASDAQ:LGVN

Longeveron (LGVN) Stock Price, News & Analysis

Longeveron logo
$1.38 +0.05 (+3.38%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.03 (+2.18%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Longeveron Stock (NASDAQ:LGVN)

Key Stats

Today's Range
$1.29
$1.38
50-Day Range
$1.26
$1.86
52-Week Range
$0.77
$6.40
Volume
101,512 shs
Average Volume
2.96 million shs
Market Capitalization
$20.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67
Consensus Rating
Buy

Company Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Longeveron Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

LGVN MarketRank™: 

Longeveron scored higher than 65% of companies evaluated by MarketBeat, and ranked 452nd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Longeveron has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Longeveron has only been the subject of 1 research reports in the past 90 days.

  • Read more about Longeveron's stock forecast and price target.
  • Earnings Growth

    Earnings for Longeveron are expected to grow in the coming year, from ($3.69) to ($1.42) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Longeveron is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Longeveron is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Longeveron has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.50% of the float of Longeveron has been sold short.
  • Short Interest Ratio / Days to Cover

    Longeveron has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Longeveron has recently decreased by 16.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Longeveron does not currently pay a dividend.

  • Dividend Growth

    Longeveron does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.50% of the float of Longeveron has been sold short.
  • Short Interest Ratio / Days to Cover

    Longeveron has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Longeveron has recently decreased by 16.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Longeveron has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Longeveron this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Longeveron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,350.00 in company stock.

  • Percentage Held by Insiders

    19.12% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 10.01% of the stock of Longeveron is held by institutions.

  • Read more about Longeveron's insider trading history.
Receive LGVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter.

LGVN Stock News Headlines

Q2 Earnings Estimate for Longeveron Issued By HC Wainwright
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Longeveron Inc.
Longeveron® to Attend BIO International Convention 2025
See More Headlines

LGVN Stock Analysis - Frequently Asked Questions

Longeveron's stock was trading at $1.73 on January 1st, 2025. Since then, LGVN stock has decreased by 20.5% and is now trading at $1.3750.
View the best growth stocks for 2025 here
.

Longeveron Inc. (NASDAQ:LGVN) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.19. The company earned $0.77 million during the quarter, compared to the consensus estimate of $0.34 million. Longeveron had a negative net margin of 967.49% and a negative trailing twelve-month return on equity of 142.43%.
Read the conference call transcript
.

Longeveron's stock reverse split on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Longeveron (LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO.

Top institutional shareholders of Longeveron include R Squared Ltd (0.16%). Insiders that own company stock include Joshua Hare, Rock Soffer, Khoso Baluch, Mohamed Wa'el Ahmed Hashad, James Clavijo, Jeffrey Pfeffer and Cathy Ross.
View institutional ownership trends
.

Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Longeveron investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
11/12/2024
Today
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LGVN
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+530.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,410,000.00
Net Margins
-967.49%
Pretax Margin
-967.49%

Debt

Sales & Book Value

Annual Sales
$2.23 million
Price / Cash Flow
N/A
Book Value
$2.68 per share
Price / Book
0.51

Miscellaneous

Free Float
12,000,000
Market Cap
$20.53 million
Optionable
Not Optionable
Beta
0.38
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:LGVN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners